1. A combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) together with temozolamide, for use in the treatment of a glioma, wherein the dose level of the phytocannabinoids and/or the temozolamide is sub-effective for the treatment of the glioma if used alone.

2. The use of a combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) together with temozolamide, in the manufacture of a medicament to treat a glioma, wherein the dose level of the phytocannabinoids and/or the temozolamide is sub-effective for the treatment of the glioma if used alone.

3. The combination or the use of the combination of phytocannabinoids as claimed in claim 1 or 2, wherein the combination of phytocannabinoids and the temozolamide are packaged for administration separately, simultaneously or sequentially.

CLAIMS

1. A combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) together with temozolamide, for use in the treatment of a glioma, wherein the dose level of the phytocannabinoids and/or the temozolamide is sub-effective for the treatment of the glioma if used alone.

2. The use of a combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) together with temozolamide, in the manufacture of a medicament to treat a glioma, wherein the dose level of the phytocannabinoids and/or the temozolamide is sub-effective for the treatment of the glioma if used alone.

3. The combination or the use of the combination of phytocannabinoids as claimed in claim 1 or 2, wherein the combination of phytocannabinoids and the temozolamide are packaged for administration separately, simultaneously or sequentially.